News & Perspective

Dec 22, 2008

Dec 22, 2008

EU panel supports innovative pandemic, seasonal flu vaccines

(CIDRAP News) – An H5N1 influenza vaccine made by Baxter International could become the first cell culture–based H5N1 influenza vaccine to be approved for marketing, following its endorsement by a committee of the European Medicines Agency (EMEA) last week.

Recommendations of the Committee for Medicinal Products for Human Use (CHMP) are usually followed by the EMEA within a few months.

Jun 17, 2008

Jun 17, 2008

Australia approves CSL's H5N1 vaccine

(CIDRAP News) – Australian authorities have approved an H5N1 avian influenza vaccine made by the Australian-based pharmaceutical company CSL Limited, giving the country a home-grown defensive tool if the virus evolves into a pandemic strain.

Jun 12, 2008

Jun 12, 2008

Baxter says cell-based H5N1 vaccine did well in trial

(CIDRAP News) – A pharmaceutical company is reporting good results in the first clinical trial of an H5N1 avian influenza vaccine that uses a whole, killed H5N1 virus grown in cell culture—a combination of techniques that entails some risk but may boost immune response and shorten production time.

May 19, 2008

May 19, 2008

EU approves its first prepandemic H5N1 vaccine

(CIDRAP News) – An H5N1 influenza vaccine made by the British pharmaceutical company GlaxoSmithKline (GSK) has become the first prepandemic vaccine to be licensed by the European Union (EU), the company announced today.

Sort Results

 

Narrow results

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»